233 million in net losses in 2022!!!!

Quote









Investors are willing to invest in the losses when the future looks promising. This is clearly the case here, as the outcome data can provide a launching pad for BA. It seems that all the “ bad news.” Is cooked into the share price, and there is strong potential for a significant op swing with the release of the CLEAR results. A paradigm shift in treatment patterns can accrue to significant results, and the cardiology community has been begging for more proven tools with different MOAs to reduce cardiovascular risk. Only directional risk is up, FOMO becomes a driver that propels share price.
 












From simply Wall Street:

It's clear from the latest estimates that Esperion Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 66% annualised revenue growth to the end of 2023 noticeably faster than its historical growth of 16% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.8% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Esperion Therapeutics is expected to grow much faster than its industry.


ESPR to the MOON!!!
 






Just knowing I live in your head is pure enjoyment. Your banter is very middle school but it's been an enjoyment the last 3 years driving you crazy. You really should seek medical attention. It's just not healthy to be a twirp. Get a life Karen hater.
 













Write your reply...
Top Bottom
Back
Quote